A New Intranasal Influenza Vector-Based Vaccine TB/FLU-04L Against Tuberculosis: Preclinical Safety Studies

Abstract

A recombinant vector vaccine TB/FLU-04L for the prevention of tuberculosis was developed in RIBSP CS MES RK and SRII. The vaccine is based on the attenuated influenza strain Flu NS₁₀₆/ESAT-6_Ag85A expressing mycobacterial antigens Esat-6 and Ag85A. This research aimed to conduct pre-clinical safety studies of the vaccine as one of the basic and mandatory stages in the development and introduction of immunobiological preparations. The studies were performed at the research centers of the Republic of Kazakhstan and the Russian Federation.

The experiment was conducted on ferrets, monkeys, and rabbits. The TB/FLU-04L vaccine was administered intranasally (7.5 lg TCID₅₀/animal). The clinical signs, body weight, temperature, hematological parameters, and local irritant effects were monitored throughout the study. The results of the study demonstrated the safety of the TB/FLU-04L intranasal vector vaccine against tuberculosis since its administration in laboratory animals led to no adverse effects in any of the monitored parameters. No influenza A virus particles were isolated from samples of nasal washes.

Keywords

tuberculosis vaccine - intranasally administration - ferrets - monkeys

Publication History

Received: 28 December 2021

Accepted: 28 February 2022

Article published online:
22 March 2022

• References

• 1 Khoshnood S, Heidary M, Haeili M, Drancourt M, Darban-Sarokhalil D, Nasiri MJ, Lohrasbi V. Novel vaccine candidates against Mycobacterium tuberculosis. Int J Biol Macromol 2018; 120: 180-188 DOI: 10.1016/j.ijbiomac.2018.08.037.
• 2 Fletcher HA. Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine. mBio 2016; 7: e01370-16 DOI: 10.1128/mBio.01370-16.
• 3 Boman G. The ongoing story of the Bacille Calmette-Guérin (BCG) vaccination. Acta Paediatr 2016; 105: 1417-1420 DOI: 10.1111/apa.13585.
• 4 Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-S53.
• 5 Jeyanathan M, Yao Y, Afkhami S, Smaill F, Xing Z. New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity. Trends Immunol 2018; 39: 419-433 DOI: 10.1016/j.it.2018.01.006.
• 6 Grover A, Troudt J, Arnett K, Izzo L, Lucas M, Strain K, McFarland C, Hall Y, McMurray D, Williams A, Dobos K, Izzo A. Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis. Tuberculosis 2012; 92: 105-111 DOI: 10.1016/j.tube.2011.09.003.
• 7 Mifsud EJ, Tai CM, Hurt AC. Animal models used to assess influenza antivirals. Expert Opin Drug Discov 2018; 13: 1131-1139 DOI: 10.1080/17460441.2018.1540586.
• 8 Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1938; 27: 493-497